Hunan Nucien Pharmaceutical Co Ltd
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascula… Read more
Hunan Nucien Pharmaceutical Co Ltd (688189) - Total Liabilities
Latest total liabilities as of June 2025: CN¥237.11 Million CNY
Based on the latest financial reports, Hunan Nucien Pharmaceutical Co Ltd (688189) has total liabilities worth CN¥237.11 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hunan Nucien Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Hunan Nucien Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hunan Nucien Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hunan Nucien Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Greenway Technology Co Ltd
SHG:688345
|
China | CN¥1.78 Billion |
|
AUPU Home Style Corp Ltd
SHG:603551
|
China | CN¥727.16 Million |
|
Aeluma, Inc
NASDAQ:ALMU
|
USA | $1.77 Million |
|
NMPGY
PINK:NMPGY
|
USA | $761.03 Million |
|
Ibersol SGPS
LS:IBS
|
Portugal | €382.13 Million |
|
Hennessy Capital Investment Corp. VII Unit
NASDAQ:HVIIU
|
USA | $8.95 Million |
|
Dat Phuong JSC
VN:DPG
|
Vietnam | ₫2.15 Trillion |
|
Rongfeng Holding Group
SHE:000668
|
China | CN¥568.27 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Hunan Nucien Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Nucien Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Nucien Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total liabilities of Hunan Nucien Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥344.13 Million | -20.67% |
| 2023-12-31 | CN¥433.80 Million | -34.10% |
| 2022-12-31 | CN¥658.24 Million | -10.67% |
| 2021-12-31 | CN¥736.89 Million | +57.84% |
| 2020-12-31 | CN¥466.87 Million | +1.17% |
| 2019-12-31 | CN¥461.45 Million | +7.01% |
| 2018-12-31 | CN¥431.23 Million | +7.77% |
| 2017-12-31 | CN¥400.14 Million | -9.74% |
| 2016-12-31 | CN¥443.35 Million | -- |